{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:44:11Z","timestamp":1790113451837,"version":"4.0.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["101034290"],"award-info":[{"award-number":["101034290"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40291-026-00829-6","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T14:47:54Z","timestamp":1770302874000},"page":"177-193","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Interlesional Heterogeneity of EGFR Mutations: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"30","author":[{"given":"Diana Ivonne","family":"Rodr\u00edguez S\u00e1nchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selin Asli","family":"\u00d6zt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Maxouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stevie","family":"van der Mierden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winnie","family":"Schats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajjad","family":"Rostami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Ursprung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petur","family":"Snaebjornsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuhir","family":"Bodalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8533-5090","authenticated-orcid":false,"given":"Regina","family":"Beets-Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"829_CR1","doi-asserted-by":"crossref","unstructured":"Khaddour K, Jonna S, Deneka A, Patel JD, Abazeed ME, Golemis E, et al. Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies. Cancers [Internet]. 2021 Jun 24 [cited 2025 Sep 18];13(13):3164. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8267708\/.","DOI":"10.3390\/cancers13133164"},{"key":"829_CR2","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/1973241","volume":"2020","author":"V Jurisic","year":"2020","unstructured":"Jurisic V, Vukovic V, Obradovic J, Gulyaeva LF, Kushlinskii NE, Djordjevi\u0107 N. EGFR polymorphism and survival of NSCLC patients treated with TKIs: a systematic review and meta-analysis. J Oncol. 2020;2020:1973241. https:\/\/doi.org\/10.1155\/2020\/1973241.","journal-title":"J Oncol"},{"key":"829_CR3","unstructured":"Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res [Internet]. 2015 Aug 15;5(9):2892\u2013911. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4633915\/."},{"issue":"1","key":"829_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40291-021-00563-1","volume":"26","author":"B Melosky","year":"2022","unstructured":"Melosky B, Kambartel K, H\u00e4ntschel M, Bennetts M, Nickens DJ, Brinkmann J, et al. Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung cancer: a meta-analysis. Mol Diagn Ther. 2022;26(1):7\u201318. https:\/\/doi.org\/10.1007\/s40291-021-00563-1.","journal-title":"Mol Diagn Ther"},{"issue":"1","key":"829_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-025-10447-w","volume":"52","author":"J Obradovi\u0107","year":"2025","unstructured":"Obradovi\u0107 J, Ni\u0161evic-Lazovi\u0107 J, Sekeru\u0161 V, Mila\u0161in J, Perin B, Jurisic V. Investigating the frequencies of EGFR mutations and EGFR single nucleotide polymorphisms genotypes and their predictive role in NSCLC patients in Republic of Serbia. Mol Biol Rep. 2025;52(1):350. https:\/\/doi.org\/10.1007\/s11033-025-10447-w.","journal-title":"Mol Biol Rep"},{"key":"829_CR6","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/6192187","volume":"2018","author":"V Juri\u0161i\u0107","year":"2018","unstructured":"Juri\u0161i\u0107 V, Obradovic J, Pavlovi\u0107 S, Djordjevic N. Epidermal growth factor receptor gene in non-small-cell lung cancer: the importance of promoter polymorphism investigation. Anal Cell Pathol (Amst). 2018;2018:6192187. https:\/\/doi.org\/10.1155\/2018\/6192187.","journal-title":"Anal Cell Pathol (Amst)"},{"issue":"21","key":"829_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13216391","volume":"13","author":"C Sha","year":"2024","unstructured":"Sha C, Lee PC. EGFR-targeted therapies: a literature review. J Clin Med. 2024;13(21):6391. https:\/\/doi.org\/10.3390\/jcm13216391.","journal-title":"J Clin Med"},{"key":"829_CR8","doi-asserted-by":"publisher","unstructured":"Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma. 2009. https:\/\/doi.org\/10.1056\/NEJMoa0810699.","DOI":"10.1056\/NEJMoa0810699"},{"key":"829_CR9","doi-asserted-by":"publisher","unstructured":"Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non\u2013small-cell lung cancer with mutated EGFR. 2010. https:\/\/doi.org\/10.1056\/NEJMoa0909530.","DOI":"10.1056\/NEJMoa0909530"},{"issue":"2","key":"829_CR10","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2022.13649","volume":"25","author":"J Obradovic","year":"2023","unstructured":"Obradovic J, Todosijevic J, Jurisic V. Side effects of tyrosine kinase inhibitors therapy in patients with non-small cell lung cancer and associations with EGFR polymorphisms: a systematic review and meta-analysis. Oncol Lett. 2023;25(2):62. https:\/\/doi.org\/10.3892\/ol.2022.13649.","journal-title":"Oncol Lett"},{"issue":"5","key":"829_CR11","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.annonc.2022.02.003","volume":"33","author":"A Passaro","year":"2022","unstructured":"Passaro A, Leighl N, Blackhall F, Popat S, Kerr K, Ahn MJ, et al. Esmo expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Ann Oncol. 2022;33(5):466\u201387. https:\/\/doi.org\/10.1016\/j.annonc.2022.02.003.","journal-title":"Ann Oncol"},{"issue":"9","key":"829_CR12","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrclinonc.2017.14","volume":"14","author":"G Siravegna","year":"2017","unstructured":"Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14(9):531\u201348. https:\/\/doi.org\/10.1038\/nrclinonc.2017.14.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"829_CR13","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2304-3865.2012.12.03","volume":"2","author":"J Bar","year":"2013","unstructured":"Bar J, Urban D, Borshtein R, Nechushtan H, Onn A. EGFR mutation in lung cancer: tumor heterogeneity and the impact of chemotherapy. Chin Clin Oncol. 2013;2(1):2. https:\/\/doi.org\/10.3978\/j.issn.2304-3865.2012.12.03.","journal-title":"Chin Clin Oncol"},{"key":"829_CR14","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.2147\/OTT.S66502","volume":"7","author":"X Cheng","year":"2014","unstructured":"Cheng X, Chen H. Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives. Onco Targets Ther. 2014;7:1689\u2013704. https:\/\/doi.org\/10.2147\/OTT.S66502.","journal-title":"Onco Targets Ther"},{"key":"829_CR15","doi-asserted-by":"crossref","unstructured":"Lee CC, Soon YY, Tan CL, Koh WY, Leong CN, Tey JCS, et al. Discordance of epidermal growth factor receptor mutation between primary lung tumor and paired distant metastases in non-small cell lung cancer: A systematic review and meta-analysis. PloS one [Internet]. 2019 Jun 19 [cited 2025 Apr 30];14(6). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31216329\/.","DOI":"10.1371\/journal.pone.0218414"},{"issue":"9","key":"829_CR16","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.jtho.2017.05.011","volume":"12","author":"R Wan","year":"2017","unstructured":"Wan R, Wang Z, Lee JJ, Wang S, Li Q, Tang F, et al. Comprehensive analysis of the discordance of EGFR mutation status between tumor tissues and matched circulating tumor DNA in advanced non-small cell lung cancer. J Thorac Oncol. 2017;12(9):1376\u201387. https:\/\/doi.org\/10.1016\/j.jtho.2017.05.011.","journal-title":"J Thorac Oncol"},{"issue":"10","key":"829_CR17","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","volume":"16","author":"C Rolfo","year":"2021","unstructured":"Rolfo C, Mack P, Scagliotti GV, Aggarwal C, Arcila ME, Barlesi F, et al. Liquid biopsy for advanced NSCLC: a consensus statement from the International Association for the Study of Lung Cancer. J Thorac Oncol. 2021;16(10):1647\u201362. https:\/\/doi.org\/10.1016\/j.jtho.2021.06.017.","journal-title":"J Thorac Oncol"},{"issue":"18","key":"829_CR18","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2017.07.10","volume":"5","author":"AP Singh","year":"2017","unstructured":"Singh AP, Li S, Cheng H. Circulating DNA in EGFR-mutated lung cancer. Ann Transl Med. 2017;5(18):379. https:\/\/doi.org\/10.21037\/atm.2017.07.10.","journal-title":"Ann Transl Med"},{"issue":"1","key":"829_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-00876-y","volume":"9","author":"A Bartolomucci","year":"2025","unstructured":"Bartolomucci A, Nobrega M, Ferrier T, Dickinson K, Kaorey N, Nadeau A, et al. Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology. NPJ Precis Oncol. 2025;9(1):84. https:\/\/doi.org\/10.1038\/s41698-025-00876-y.","journal-title":"NPJ Precis Oncol"},{"issue":"2","key":"829_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100399","volume":"7","author":"E Heitzer","year":"2022","unstructured":"Heitzer E, van den Broek D, Denis MG, Hofman P, Hubank M, Mouliere F, et al. Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer. ESMO Open. 2022;7(2):100399. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100399.","journal-title":"ESMO Open"},{"issue":"8","key":"829_CR21","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","volume":"33","author":"J Pascual","year":"2022","unstructured":"Pascual J, Attard G, Bidard FC, Curigliano G, De Mattos-Arruda L, Diehn M, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO precision medicine working group. Ann Oncol. 2022;33(8):750\u201368. https:\/\/doi.org\/10.1016\/j.annonc.2022.05.520.","journal-title":"Ann Oncol"},{"issue":"6","key":"829_CR22","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1158\/1078-0432.CCR-13-2482","volume":"20","author":"GR Oxnard","year":"2014","unstructured":"Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O\u2019Connell A, Messineo MM, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res [Internet]. 2014;20(6):1698\u2013705. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2482.","journal-title":"Clin Cancer Res [Internet]."},{"issue":"10","key":"829_CR23","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.jtho.2016.05.035","volume":"11","author":"KL Reckamp","year":"2016","unstructured":"Reckamp KL, Melnikova VO, Karlovich C, Sequist LV, Camidge DR, Wakelee H, et al. A highly sensitive and quantitative test platform for detection of NSCLC EGFR mutations in urine and plasma. J Thorac Oncol. 2016;11(10):1690\u2013700. https:\/\/doi.org\/10.1016\/j.jtho.2016.05.035.","journal-title":"J Thorac Oncol"},{"issue":"7","key":"829_CR24","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1097\/JTO.0b013e318219aaae","volume":"6","author":"M Shingyoji","year":"2011","unstructured":"Shingyoji M, Kageyama H, Sakaida T, Nakajima T, Matsui Y, Itakura M, et al. Detection of epithelial growth factor receptor mutations in cerebrospinal fluid from patients with lung adenocarcinoma suspected of neoplastic meningitis. J Thorac Oncol. 2011;6(7):1215\u201320. https:\/\/doi.org\/10.1097\/JTO.0b013e318219aaae.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"829_CR25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.resinv.2015.07.001","volume":"54","author":"S Sasaki","year":"2016","unstructured":"Sasaki S, Yoshioka Y, Ko R, Katsura Y, Namba Y, Shukuya T, et al. Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure. Respir Investig. 2016;54(1):14\u20139. https:\/\/doi.org\/10.1016\/j.resinv.2015.07.001.","journal-title":"Respir Investig"},{"issue":"Supplement","key":"829_CR26","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.4103\/ijc.ijc_438_21","volume":"59","author":"K Prabhash","year":"2022","unstructured":"Prabhash K, Biswas B, Khurana S, Batra U, Biswas G, Advani SH, et al. CONCORDANCE: A real-world evidence study to evaluate the concordance of detecting epidermal growth factor receptor (EGFR) mutation by circulating tumor DNA* versus tissue biopsy in patients with metastatic non-small cell lung cancer: A real-world evidence study to evaluate the concordance of detecting epidermal growth factor receptor (EGFR) mutation by circulating tumor DNA* versus tissue biopsy in patients with metastatic non-small cell lung cancer. Indian J Cancer [Internet]. 2022;59(Supplement):S11\u20138. https:\/\/doi.org\/10.4103\/ijc.ijc_438_21.","journal-title":"Indian J Cancer [Internet]."},{"key":"829_CR27","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med [Internet]. 2009 Jul 21 [cited 2025 Apr 30];6(7). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/19621072\/.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"829_CR28","unstructured":"PROSPERO [Internet]. [cited 2025 Apr 30]. Available from: https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42024615727."},{"issue":"5676","key":"829_CR29","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez JG, J\u00e4nne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497\u2013500. https:\/\/doi.org\/10.1126\/science.1099314.","journal-title":"Science"},{"issue":"21","key":"829_CR30","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129\u201339. https:\/\/doi.org\/10.1056\/NEJMoa040938.","journal-title":"N Engl J Med"},{"key":"829_CR31","doi-asserted-by":"crossref","unstructured":"Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Internal Med [Internet]. 2011 Oct 18 [cited 2025 Apr 30];155(8). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22007046\/.","DOI":"10.7326\/0003-4819-155-8-201110180-00009"},{"issue":"3","key":"829_CR32","doi-asserted-by":"publisher","first-page":"142","DOI":"10.14740\/wjon1204","volume":"10","author":"N Kumari","year":"2019","unstructured":"Kumari N, Singh S, Haloi D, Mishra SK, Krishnani N, Nath A, et al. Epidermal growth factor receptor mutation frequency in squamous cell carcinoma and its diagnostic performance in cytological samples: a molecular and immunohistochemical study. World J Oncol. 2019;10(3):142\u201350. https:\/\/doi.org\/10.14740\/wjon1204.","journal-title":"World J Oncol"},{"issue":"2","key":"829_CR33","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.advms.2021.06.003","volume":"66","author":"A Szpechcinski","year":"2021","unstructured":"Szpechcinski A, Bryl M, Wojcik P, Czyzewicz G, Wojda E, Rudzinski P, et al. Detection of EGFR mutations in liquid biopsy samples using allele-specific quantitative PCR: a comparative real-world evaluation of two popular diagnostic systems. Adv Med Sci. 2021;66(2):336\u201342. https:\/\/doi.org\/10.1016\/j.advms.2021.06.003.","journal-title":"Adv Med Sci"},{"key":"829_CR34","doi-asserted-by":"publisher","first-page":"i38","DOI":"10.1093\/annonc\/mdx706","volume":"29","author":"JW Goldman","year":"2018","unstructured":"Goldman JW, Noor ZS, Remon J, Besse B, Rosenfeld N. Are liquid biopsies a surrogate for tissue EGFR testing? Ann Oncol. 2018;29:i38-46. https:\/\/doi.org\/10.1093\/annonc\/mdx706.","journal-title":"Ann Oncol"},{"issue":"19","key":"829_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70078","volume":"13","author":"F Fan","year":"2024","unstructured":"Fan F, Jiang G, Lv J, Wang H, Li W, Liu C, et al. Analytical and clinical validation of a NGS panel in detecting targetable variants from ctDNA of metastatic NSCLC patients. Cancer Med. 2024;13(19):e70078. https:\/\/doi.org\/10.1002\/cam4.70078.","journal-title":"Cancer Med"},{"issue":"1","key":"829_CR36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3233\/cbm-220079","volume":"36","author":"P Incharoen","year":"2023","unstructured":"Incharoen P, Jinawath A, Arsa L, Kamprerasart K, Trachu N, Monnamo N, et al. Clinical correlations with EGFR circulating tumor DNA testing in all-stage lung adenocarcinoma. Cancer Biomark. 2023;36(1):71\u201382. https:\/\/doi.org\/10.3233\/cbm-220079.","journal-title":"Cancer Biomark"},{"issue":"11","key":"829_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8111758","volume":"8","author":"CY Kuo","year":"2019","unstructured":"Kuo CY, Lee MH, Tsai MJ, Yang CJ, Hung JY, Chong IW. The factors predicting concordant epidermal growth factor receptor (EGFR) mutation detected in liquid\/tissue biopsy and the related clinical outcomes in patients of advanced lung adenocarcinoma with EGFR mutations. J Clin Med. 2019;8(11):1758. https:\/\/doi.org\/10.3390\/jcm8111758.","journal-title":"J Clin Med"},{"issue":"2","key":"829_CR38","doi-asserted-by":"publisher","first-page":"484","DOI":"10.4143\/crt.2023.712","volume":"56","author":"JY Lee","year":"2024","unstructured":"Lee JY, Jeon S, Jun HR, Sung CO, Jang SJ, Choi CM, et al. Revolutionizing non-small cell lung cancer diagnosis: ultra-high-sensitive ctDNA analysis for detecting hotspot mutations with long-term stored plasma. Cancer Res Treat. 2024;56(2):484\u2013501. https:\/\/doi.org\/10.4143\/crt.2023.712.","journal-title":"Cancer Res Treat"},{"issue":"7957","key":"829_CR39","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41586-023-05783-5","volume":"616","author":"AM Frankell","year":"2023","unstructured":"Frankell AM, Dietzen M, Al Bakir M, Lim EL, Karasaki T, Ward S, et al. The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature. 2023;616(7957):525\u201333. https:\/\/doi.org\/10.1038\/s41586-023-05783-5.","journal-title":"Nature"},{"issue":"5","key":"829_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000919","volume":"5","author":"A Passaro","year":"2020","unstructured":"Passaro A, Malapelle U, Del Re M, Attili I, Russo A, Guerini-Rocco E, et al. Understanding EGFR heterogeneity in lung cancer. ESMO Open. 2020;5(5):e000919. https:\/\/doi.org\/10.1136\/esmoopen-2020-000919.","journal-title":"ESMO Open"},{"issue":"1","key":"829_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02595-8","volume":"20","author":"M Li","year":"2022","unstructured":"Li M, Chen J, Zhang B, Yu J, Wang N, Li D, et al. Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028). BMC Med. 2022;20(1):398. https:\/\/doi.org\/10.1186\/s12916-022-02595-8.","journal-title":"BMC Med"},{"issue":"5","key":"829_CR42","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1200\/PO.20.00292","volume":"5","author":"SK Cheok","year":"2021","unstructured":"Cheok SK, Narayan A, Arnal-Estape A, Gettinger S, Goldberg SB, Kluger HM, et al. Tumor DNA mutations from intraparenchymal brain metastases are detectable in CSF. JCO Precis Oncol [Internet]. 2021;5(5):163\u201372. https:\/\/doi.org\/10.1200\/PO.20.00292.","journal-title":"JCO Precis Oncol [Internet]"},{"issue":"1","key":"829_CR43","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-01931-7","volume":"16","author":"K Kunimasa","year":"2025","unstructured":"Kunimasa K, Aohara D, Nishino K. Driver mutation detected in cerebrospinal fluid despite negative liquid biopsy results. Discover Oncol. 2025;16(1):145. https:\/\/doi.org\/10.1007\/s12672-025-01931-7.","journal-title":"Discover Oncol"},{"issue":"1","key":"829_CR44","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-025-02880-9","volume":"149","author":"G Dwarshuis","year":"2025","unstructured":"Dwarshuis G, Kroon LL, Brandsma D, Noske DP, Best MG, Sol N. Liquid biopsies for the monitoring of gliomas and brain metastases in adults. Acta Neuropathol. 2025;149(1):37. https:\/\/doi.org\/10.1007\/s00401-025-02880-9.","journal-title":"Acta Neuropathol"},{"key":"829_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlb.2024.100170","volume":"6","author":"M Izhar","year":"2024","unstructured":"Izhar M, Ahmad Z, Moazzam M, Jader A. Targeted liquid biopsy for brain tumors. J Liq Biopsy. 2024;6:100170. https:\/\/doi.org\/10.1016\/j.jlb.2024.100170.","journal-title":"J Liq Biopsy"},{"issue":"4","key":"829_CR46","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1515\/cclm-2019-0896","volume":"58","author":"JS Lee","year":"2020","unstructured":"Lee JS, Kim M, Seong MW, Kim HS, Lee YK, Kang HJ. Plasma vs. serum in circulating tumor DNA measurement: characterization by DNA fragment sizing and digital droplet polymerase chain reaction. Clin Chem Lab Med (CCLM). 2020;58(4):527\u201332. https:\/\/doi.org\/10.1515\/cclm-2019-0896.","journal-title":"Clin Chem Lab Med (CCLM)"},{"issue":"7","key":"829_CR47","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1093\/clinchem\/hvaa103","volume":"66","author":"F Pittella-Silva","year":"2020","unstructured":"Pittella-Silva F, Chin YM, Chan HT, Nagayama S, Miyauchi E, Low SK, et al. Plasma or serum: which is preferable for mutation detection in liquid biopsy? Clin Chem. 2020;66(7):946\u201357. https:\/\/doi.org\/10.1093\/clinchem\/hvaa103.","journal-title":"Clin Chem"},{"issue":"3","key":"829_CR48","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1016\/j.cllc.2023.01.003","volume":"24","author":"MC Tran","year":"2023","unstructured":"Tran MC, Strohbehn GW, Karrison TG, Rouhani SJ, Segal JP, Shergill A, et al. Brief report: Discordance between liquid and tissue biopsy-based next-generation sequencing in lung adenocarcinoma at disease progression. Clin Lung Cancer [Internet]. 2023;24(3):e117\u201321. https:\/\/doi.org\/10.1016\/j.cllc.2023.01.003.","journal-title":"Clin Lung Cancer [Internet]"},{"issue":"4","key":"829_CR49","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1007\/s11033-021-06379-w","volume":"48","author":"J Obradovic","year":"2021","unstructured":"Obradovic J, Todosijevic J, Jurisic V. Application of the conventional and novel methods in testing EGFR variants for NSCLC patients in the last 10 years through different regions: a systematic review. Mol Biol Rep. 2021;48(4):3593\u2013604. https:\/\/doi.org\/10.1007\/s11033-021-06379-w.","journal-title":"Mol Biol Rep"},{"issue":"4","key":"829_CR50","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3978\/j.issn.2218-6751.2014.08.04","volume":"3","author":"T Mitsudomi","year":"2014","unstructured":"Mitsudomi T. Molecular epidemiology of lung cancer and geographic variations with special reference to EGFR mutations. Transl Lung Cancer Res [Internet]. 2014;3(4):205\u201311. https:\/\/doi.org\/10.3978\/j.issn.2218-6751.2014.08.04.","journal-title":"Transl Lung Cancer Res [Internet]"},{"key":"829_CR51","doi-asserted-by":"crossref","unstructured":"Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Thorac Oncol. 2018 Mar [cited 2025 Dec 17];13(3). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29396253\/.","DOI":"10.5858\/arpa.2017-0388-CP"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-026-00829-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-026-00829-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-026-00829-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:33:33Z","timestamp":1773822813000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-026-00829-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["829"],"URL":"https:\/\/doi.org\/10.1007\/s40291-026-00829-6","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"3 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"D.I.R.S. received funding from the European Union\u2019s Horizon 2020 research and innovation program under the Marie Sk\u0142odowska-Curie grant agreement number 101034290 (EMERALD International PhD Program for Medical Doctors).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"D.I.R.S., S.A.\u00d6., O.M., S.v.d.M., W.S., S.R., S.U., P.S., Z.B., and R.B.-T. declare that they have no conflicts of interest that might be relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent (participation & publication)"}},{"value":"D.I.R.S: Conceptualisation; methodology; investigation (first screening, second screening, snowballing, data extraction); data curation; formal analysis; visualisation direction; writing (original draft, review, and editing). S.A.\u00d6.: Investigation (second screening, snowballing, data extraction); data curation; writing (review and editing). O.M.: Visualisation (figure preparation and editing); writing (review and editing). S.v.d.M.: Investigation (literature search); writing (review and editing). W.S.: Investigation (literature search); writing (review and editing). S.R.: Methodological input; writing (review and editing). S.U.: Methodological input; writing (review and editing). P.S.: Supervision, methodological input; writing (review and editing). Z.B.: Conceptualisation; methodology; investigation (first screening); formal analysis; writing (original draft, review, and editing). R.B.-T: Supervision; project administration; writing (review and editing). All authors have read and approved the final version of the article.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Data generated or analysed during this study are included in this published article.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}